COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Nanobiotix presents part 1 data from JNJ-1900 (NBTXR3) in lung cancer at ESTRO 2026, showing promising responses. JNJ-1900 is a novel oncology product activated by radiotherapy -
-
COMMUNIQUÉ DE PRESSE
The publication of the audited financial statements for 2025 will be postponed to 12 June 2026 – management does not expect any significant changes to the figures already published
elumeo SE postpones the publication of its audited financial statements for 2025 to 12 June 2026, expecting no significant changes. Details on ongoing audit and ESEF certification -
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
Onco-Innovations advances CMC program by initiating analytical method validation for ONC010 API, partnering with Dalton Pharma Services for IND-enabling studies and Phase I clinical development support -
-
COMMUNIQUÉ DE PRESSE
Jericho Energy Ventures Announces Transition to Semi-Annual Reporting to Enhance Efficiency
Jericho Energy Ventures Inc. announces transition to semi-annual financial reporting framework under Blanket Order 51-933. Company to focus on business objectives with reduced reporting burden
